Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer ID6589 Consultation on suggested remit, draft scope and provisional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results